Executives
?
Dickinson Andrew D
Chief Financial Officer
Gilead Sciences, Inc.
US, Foster City [HQ]
CIK
1310204
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
96,891
Price per Share :
$91.84
Equivalence :
$8,898,469.44
Transaction History
-
A96,891 Shares After TransactionValue : $n/a$0.0Transaction Date : 01/31/24
-
Footnotes
-
-
Footnotes:#1 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2022 and March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.#2 Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2021. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.
-
A152,846 Shares After TransactionValue : $n/a$0.0Transaction Date : 01/31/24
-
Footnotes
-
-
Footnotes:#1 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2022 and March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.#2 Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2021. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.
-
F129,436 Shares After TransactionValue : $10,129,661.36$1,832,066.60Transaction Date : 01/31/24
-
Footnotes
-
-
Footnotes:#1 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2022 and March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.#2 Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2021. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.
-
M132,781 Shares After TransactionValue : $n/a$0.0Transaction Date : 03/10/24
-
Footnotes
-
-
Footnotes:#1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.#2 Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
-
M139,488 Shares After TransactionValue : $n/a$0.0Transaction Date : 03/10/24
-
Footnotes
-
-
Footnotes:#1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.#2 Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.